Adam Bruce

Adam Bruce is an experienced executive with a significant background in the pharmaceutical and biotechnology sectors. Since March 2002, Adam has served as the Chief Executive Officer, Founder, and Board Member of TikoMed AB, where leadership spans across various roles, including Working Chairman. Since July 2020, Adam has been the Chairman of Abarceo Pharma, where efforts are directed towards innovative solutions for Type 2 Diabetes. Adam also owns WaveSeven AB, active since 2014. Educational credentials include a degree from Lund University (1993-1999), completion of Styrelse Akademin (2010), and participation in the Executive Foundation program at the Lund School of Economics and Management (2007-2008).